May 8, 2018 08:03 PM EDT

Stormy Daniels’ lawyer: Novartis made $400K in 'suspicious' payments to Trump attorney Michael Cohen

John Carroll

Editor & Founder

Stormy Daniels’ attorney Michael Avenatti has outlined a series of “suspicious financial transactions” involving close to $400,000 in payments Novartis made to the account of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stormy Daniels’ lawyer: Novartis made $400K in 'suspicious' payments to Trump attorney Michael Cohen

John Carroll

Editor & Founder

Sign up to read this article for free.

What will pharma's share buyback shopping spree mean for M&A?

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Stormy Daniels’ lawyer: No­var­tis made $400K in 'sus­pi­cious' pay­ments to Trump at­tor­ney Michael Co­hen

John Carroll

Editor & Founder

Sign up to read this article for free.

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

IN8bio’s Phase 1 AML da­ta; Lay­offs at Q32 Bio and Third Har­mon­ic

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Stormy Daniels’ lawyer: Novartis made $400K in 'suspicious' payments to Trump attorney Michael Cohen

What will pharma's share buyback shopping spree mean for M&A?

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers